Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral bifidobacterium triplex in mild to moderate pemphigus
ChiCTR2400087412Phase 4Not yet recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Jul 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Golden Bifid in pemphigus vulgaris (PV) and Pemphigus erythematosus (PE) (2 arms), sponsored by The Second Xiangya Hospital. Primary endpoints: Dsg1 antibody level, Dsg3 antibody level and 4 more. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
Golden Bifid
03
Conditions
pemphigus vulgaris (PV)Pemphigus erythematosus (PE)
Beyond the preview
Go deeper on ChiCTR2400087412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087412.